TCM
TNGX icon

TCG Crossover Management’s Tango Therapeutics TNGX Stock Holding History

TCG Crossover Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284M Sell
9,081,201
-1,449,870
-14% -$35.8M 6.82% 2
2026
Q1 		$220M Sell
10,531,071
-2,231,023
-17% -$31.1M 6.3% 3
2025
Q4 		$113M Buy
12,762,094
+4,225,898
+50% +$36.4M 3.74% 4
2025
Q3 		$71.7M Sell
8,536,196
-2,199,804
-20% -$14.9M 3.53% 6
2025
Q2 		$55M Hold
10,736,000
– – 6.28% 2
2025
Q1 		$14.7M Hold
10,736,000
– – 2.01% 23
2024
Q4 		$33.2M Buy
+10,736,000
New +$49.8M 3.24% 10
2022
Q4 		– Sell
-1,172,250
Closed -$4.24M – 24
2022
Q3 		$4.24M Hold
1,172,250
– – 1.27% 16
2022
Q2 		$5.31M Sell
1,172,250
-82,250
-7% -$498K 2.26% 14
2022
Q1 		$9.51M Buy
+1,254,500
New +$10.9M 3.82% 10

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCG Crossover Management's TNGX Position: Q2 2026 in Review

TCG Crossover Management reduced its Tango Therapeutics (TNGX) stake by 14% in Q2 2026, selling an estimated $35.8M and leaving 9,081,201 shares worth $284M. The position accounts for 6.82% of the portfolio, ranked #2.

TCG Crossover Management first reported a position in TNGX in Q1 2022 and has held it in 10 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • TCG Crossover Management held 9,081,201 shares of Tango Therapeutics worth $284M as of Q2 2026.
  • TCG Crossover Management sold 1,449,870 Tango Therapeutics shares in Q2 2026, an estimated $35.8M.
  • Tango Therapeutics made up 6.82% of TCG Crossover Management's portfolio in Q2 2026, its #2 holding.
  • TCG Crossover Management first reported a position in Tango Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.